Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc transporter ZIP1, encoded by the SLC39A1 gene, is a primary mediator of zinc uptake into the cytosol from the extracellular environment. In human skin fibroblasts, ZIP1 and related members of the SLC39A family are essential for maintaining intracellular zinc levels, which are critical for collagen synthesis, DNA repair, and antioxidant defense. Dysregulation of zinc uptake is linked to various pathologies, including skin disorders, impaired wound healing, and certain cancers where ZIP1 expression is often downregulated to prevent zinc-induced apoptosis. While ZIP1 itself is rarely the direct target of small molecule drugs, it is a critical component of the pharmacological profile for zinc-based therapies and ionophores used in treating deficiency and neurodegenerative diseases.
ZIP1 facilitates the influx of zinc ions from the extracellular space or intracellular organelles into the cytosol to maintain cellular zinc homeostasis and support zinc-dependent enzymatic activities.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc transporter ZIP1 (SLC39A1) (ZIP1).